<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235257</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008961</org_study_id>
    <nct_id>NCT04235257</nct_id>
  </id_info>
  <brief_title>Intradermal, Fractional Dose of HPV Vaccines:</brief_title>
  <official_title>Immunogenicity of Fractional Dose of the Bivalent and Nonavalent Intradermal HPV Vaccines.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional
      dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington.
      Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months,
      and 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HPV antibody detection after fractional HPV vaccination</measure>
    <time_frame>12 months</time_frame>
    <description>HPV antibody response after delivery of a single, intradermal, fractional dose of the HPV-2 or HPV-9 vaccines</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HPV Infection</condition>
  <condition>HPV Vaccine</condition>
  <arm_group>
    <arm_group_label>Bivalent HPV vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonavalent HPV vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV vaccine</intervention_name>
    <description>Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose</description>
    <arm_group_label>Bivalent HPV vaccine</arm_group_label>
    <arm_group_label>Nonavalent HPV vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 27-45 years at enrollment

          -  Not intending to receive the HPV vaccine series for the duration of the study
             participation

          -  Willing and able to provide written informed consent, undergo clinical evaluation, and
             adhere to follow-up schedule

        Exclusion Criteria:

          -  Prior immunization with HPV-vaccine (Cervarix, Gardasil-4, Gardasil-9)

          -  Currently pregnant or breastfeeding

          -  Immune deficiency or other immune disorder

          -  HIV infection or continued high risk for HIV; patients at risk for HIV who do not have
             a negative HIV test in the last 6 months will be excluded

          -  Cancer or chemotherapy (current, within 6 months, or anticipated in the future) except
             for fully excised non-melanoma skin cancer)

          -  Unstable medical condition (e.g., malignant hypertension, poorly controlled diabetes,

          -  Known allergy to vaccine components

          -  Prior history of HPV-associated cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>27 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Wald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UW Virology Research Clinic</last_name>
    <phone>206-520-4340</phone>
    <email>vrc@uw.edu</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Anna Wald</investigator_full_name>
    <investigator_title>Head Division of Allergy and Infectious Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

